MedTrace Logo

Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients

NCT00937079 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2015-01-09

No results posted yet for this study

Summary

The purpose of this study is to determine whether the investigators' new imaging modality (111In-exendin-4) has advantages in detecting insulinomas in comparison to conventional imaging.

Conditions

Interventions

OTHER

111In-exendin-4 imaging

90-100 megabecquerel (MBq) (30 microgram or less) 111In-exendin-4 IV once

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Damian Wild, MD · University Hospital, Basel, Switzerland

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00937079 on ClinicalTrials.gov